HEALTHCARE - Research Editorial

A new Covid-19 wave has hit China, with over ten lakh deaths predicted in the coming days

China on Monday (December 19, 2022) finally reported its first Covid-19-related deaths in weeks amid rising doubts over whether the official count was capturing the full toll of the virus.

The country of 1.4 billion people reported five new fatalities on December 19, up from two the previous day, bringing the official death toll to 5,242. The new fatalities were the first to be reported by the National Health Commission (NHC) since December 3, days before Beijing announced that it was lifting strict Covid-19 curbs which had largely kept the disease in check for three years but triggered widespread protests last month.

China also reported 2,722 new symptomatic coronavirus infections on December 19, up from 1,995 the previous day. China reported 2,656 new local cases, up from 1,918 the day before, excluding imported infections. As of Monday, mainland China has confirmed 3,83,175 Covid-19 cases with symptoms. However, Covid-19 cases and deaths are expected to rise in the coming months as the virus continues to ravage cities following Xi Jinping’s government’s relaxation of strict anti-virus controls.

Last week, China’s chief epidemiologist Wu Zunyou stated that the country was in the midst of the first of three Covid-19 waves that were expected this winter. On Monday, Beijing city official Xu Hejian also stated that the virus was rapidly spreading throughout the capital.

More restrictions will be lifted, with previously closed underground venues ranging from bars to internet cafes allowed to reopen, according to Beijing city official Xu Hejian.

While top officials have downplayed the threat posed by the Omicron strain of the virus in recent weeks, officials are still concerned about the elderly, who have been hesitant to get vaccinated.

Some fear that China’s Covid-19 death toll will exceed 10 lakh in the coming days.

The lifting of Covid-19 restrictions by China could result in an increase in cases and over 10 lakh deaths.

Gravitas: China faces three Covid waves in three months (WION)

Gravitas: China stares at 3 Covid waves in 3 months

According to new projections from the Institute of Health Metrics and Evaluation (IHME) in the United States, China’s abrupt lifting of its stringent Covid-19 curbs could result in an increase in cases and over 10 lakh deaths next year.

According to the group’s projections, coronavirus cases in China will peak around April 1, 2023, with 3,22,000 deaths.

By then, a third of China’s population will have been infected, according to IHME Director Christopher Murray.

“Nobody thought they would stick to zero-COVID as long as they did,” he said last week when the IHME projections were released online.

China’s zero-Covid policy may have been effective in keeping earlier variants of the virus at bay, but the high transmissibility of Omicron variants made it unsustainable, according to Murray.

Other experts predict that 60% of China’s population will eventually be infected, with a peak in January, with vulnerable populations such as the elderly and those with pre-existing conditions bearing the brunt of the burden.

China’s main concerns are its large pool of susceptible individuals, the use of less effective vaccines, and low vaccine coverage among those aged 80 and older, who are most at risk of severe disease.

China has already seen an increase in infections since lifting some of the world’s toughest Covid-19 restrictions this month in response to unprecedented public protests.

You May Be Also Interested in:

Follow us for more updates on Twitter, Tumblr, LinkedIn

Covid-19 was a ‘man-made’ virus: According to a scientist who worked at the Wuhan lab

According to The New York Post, a US-based scientist who worked at a research lab in China’s Wuhan revealed Monday that Covid-19 was a “man-made virus” that had leaked from the facility.

Andrew Huff, who previously worked for the EcoHealth Alliance, a New York-based non-profit dedicated to the study of infectious diseases, stated that the coronavirus had leaked from the Wuhan Institute of Virology in China more than two years ago. He also accused authorities of the “worst US intelligence failure since 9/11.”

Huff claims in his new book, The Truth About Wuhan, that the US government funded coronaviruses in China. With no biosafety safeguards in place, China’s gain-of-function experiments — which are used to genetically alter organisms in order to improve their biological functions — resulted in a leak at the Wuhan lab.

According to The Sun, epidemiologist Huff revealed in his book that “foreign laboratories did not have adequate control measures in place to ensure proper biosafety, biosecurity, and risk management, ultimately resulting in the lab leak at the Wuhan Institute of Virology.”

EcoHealth Alliance has been studying coronaviruses in bats for over a decade, with funding from the National Institutes of Health, and has formed close ties with the Wuhan lab. Huff worked for the non-profit from 2014 to 2016, rising to the position of vice president in 2015.

“China knew this was a genetically engineered agent from the start,” Huff wrote. “I was terrified by what I saw,” Huff, a Michigan Army veteran, told The Sun Online. “All we were doing was handing them bioweapon technology.”

Over the last two years, the Wuhan lab has been at the centre of global debates about the origins of the coronavirus. The Chinese government and Wuhan lab officials have repeatedly denied the allegations, labelling the theory that the virus originated in China’s lab facility “baseless.” However, top researchers have continued to investigate the virus’s origins.

In February 2022, a World Health Organization (WHO) expert group sent two letters to senior Chinese government officials requesting information about the first human cases of COVID-19 in the city of Wuhan. The experts at WHO asserted that numerous studies in this field of research should be conducted “with the staff in the laboratories tasked with managing and implementing biosafety and biosecurity,” which would then lead to revelations about how viruses related to COVID-19 were managed.

You May Be Also Interested in:

Follow us for more updates on Twitter, Tumblr, LinkedIn

World Diabetes Day: Educate today to protect tomorrow: Diabetes affects around 422 million people worldwide

On World Diabetes Day, the World Health Organization (WHO) calls for expanded access to excellent diabetes education for health and care providers, the general public, and people living with diabetes as part of efforts to attain universal access to quality, affordable diabetes care.

Diabetes affects around 422 million people worldwide, and diabetes is directly responsible for 1.5 million fatalities each year. Diabetes is estimated to affect more than 96 million people in the WHO South-East Asia Region, with another 96 million being pre-diabetic, resulting in at least 600,000 deaths each year. Diabetes prevalence in the Region is expected to rise by 68% by 2045 unless urgent action is taken.

Every year on November 14, World Diabetes Day is observed to draw people’s attention to the health risks posed by diabetes and how to avoid them.

Every year on November 14, World Diabetes Day is commemorated to draw people’s attention to the health risks posed by diabetes and how to avoid them. The huge achievement of insulin discovery by two outstanding scientists, Sir Frederick Banting and Charles Best, is commemorated on this day. The International Diabetes Federation (IDF) will be organising activities on the day, so look for a local event! Any assistance or support you can provide for this cause would be highly appreciated by everyone involved.

What is Diabetes?

Diabetes is a leading cause of blindness, kidney failure, heart attack, stroke, and amputation of lower limbs. A healthy diet, physical activity, and abstaining from tobacco use can all help to prevent or delay type 2 diabetes. Diabetes can also be controlled and its repercussions minimised or postponed through medication, routine screening, and treatment for complications. Diabetes is a chronic condition that arises when the pancreas does not create enough insulin or when the body does not use the insulin that is produced adequately. This causes an increase in the concentration of glucose in the blood (hyperglycaemia).

Diabetes Types:

Type 1 diabetes (also known as insulin-dependent diabetes or childhood-onset diabetes) is characterised by a lack of insulin production.

Type 2 diabetes (also known as non-insulin-dependent diabetes or adult-onset diabetes) is caused by the body’s inefficient utilisation of insulin. It is frequently caused by high body weight and physical inactivity.

Gestational diabetes is hyperglycemia that appears during pregnancy.

The Importance of World Diabetes Day 2022

This day is primarily observed to raise diabetes awareness through programmes that reach over one billion people worldwide. Furthermore, it promotes IDF advocacy initiatives all year. It contributes to the recognition of the need of adopting coordinated action to combat diabetes.

The UN Resolution that established World Diabetes Day in 2007 is represented by a blue circle emblem. This emblem represents diabetes awareness and the global diabetes community’s togetherness.

Diabetes education must be enhanced in order to help stop the growth in diabetes and protect future generations. From the ground up, health and care staff must have the means and knowledge to detect diabetes early and adequately care for diabetics. Diabetes patients must have access to detailed information on how to best manage their illness, which may involve medication adherence and regular check-ups. Furthermore, the general public must be fully aware of how to prevent diabetes, such as through a healthy lifestyle, as well as how to detect its signs and symptoms, such as the need to urinate frequently, thirst, constant hunger, weight loss, vision changes, and fatigue.

History of World Diabetes Day:

The International Diabetes Federation (IDF) and the World Health Organization declared World Diabetes Day for the first time in 1991. (WHO). The date of November 14 was chosen as World Diabetes Day because it was the birth anniversary of Frederick Banting, who developed insulin with Charles Best. And in 1991, the day commemorated his 100th birthday anniversary, therefore it was declared World Diabetes Day to encourage diabetes awareness all over the world.

You May Be Also Interested in:

Follow us for more updates on Twitter, Tumblr, Linkedin

Healthcare Research Studies Published by the Quintile Insights

Healthcare-Quintile Insights

offers an extensive repository of reports that scrutinize all these aspects of the healthcare industry in detail to help key opinion leaders to make strategic decisions on diversification, expansion, and other strategic and marketing initiatives.

Nowadays, Healthcare is a crucial topic that concerns everyone from individuals to world governments. Trillions of dollars are spent on healthcare facilities, medical research and development, healthcare production, marketing, and distribution, including healthcare services.
by quintileinsights

Earthquake of magnitude 6.6 strikes rocks western Nepal, with tremors reported as far away as New Delhi

An earthquake hit west Nepal’s highlands early Wednesday, killing at least six people who were sleeping in their homes, according to a government official.

The tremor was felt as far away as New Delhi, India’s capital, which is around 400 kilometres (250 miles) west of the epicentre.

According to Kalpana Shrestha, the chief officer of Doti district, six people were killed when their dwellings in a remote, sparsely populated mountain community were crushed. Five more people were hurt.

A 6.3-magnitude earthquake struck the lower Himalayan region early Wednesday morning, November 9, causing tremors to tear through north India and portions of Nepal and jolting people out of their sleep in dozens of cities and villages. Strong earthquake shocks were felt in Delhi and the nearby areas of Ghaziabad and Gurugram, as well as in Lucknow, jolting people awake. Here are some recent developments:

*Earthquake of magnitude 6.6 strikes rocks western Nepal*: **Research** **Editorial**

The earthquake, which struck at 2:12 a.m. local time, frightened people in mountain communities, forcing many to spend the night outside, according to Shrestha.

She stated that security forces had been sent to the rural communities to assist with the rescue effort. There were reports of houses being damaged in various areas, but no fresh casualties were reported.

Videos released on social media showed residents moving debris by hand to find casualties buried by earthquake-damaged buildings, as well as shining cell phone lights to shift the heaps of wood and stones used to build dwellings in most mountain villages.

The majority of the mountain settlements can only be accessed by foot, and there are no highways to transport heavy equipment to aid in the rescue.

In a statement, Prime Minister Sher Bahadur Deuba said he has directed government authorities to provide urgent support to victims and their families, as well as all necessary medical care to those injured.

The preliminary magnitude was 6.6, according to Nepal’s National Earthquake Monitoring and Research Center. The early data of a 5.6 magnitude earthquake with a depth of 15.7 kilometres (9.8 miles) and an epicentre 21 kilometres (13 miles) east of Dipayal were released by the US Geological Survey.

Earthquakes are widespread in Nepal’s hilly terrain, which is home to the world’s tallest peak. In 2015, a 7.8 magnitude earthquake killed 9,000 people and injured thousands more.

Most Read From Research Editorial:

Follow us for more updates on Twitter, Tumblr

GSK’s blood cancer treatment fails to meet its primary trial target, causing its stock to plummet

GSK’s blood cancer medicine Blenrep failed to meet the primary goal of a late-stage research designed to demonstrate that it was superior to an existing treatment on the market, the company announced on Monday.

GSK’s shares plummeted 3% after its comments, which raised concerns that Blenrep’s regulatory licence may be revoked. Oncology is a significant area of concentration for GSK as a separate prescription pharmaceutical and vaccine business.

GSK said that Blenrep did not reach the primary endpoint of “progression-free survival,” or the time a person lives with the disease without it worsening following therapy, in patients with relapsed or refractory multiple myeloma.

The business decided to buy Sierra Oncology in April, acquiring access to its primary experimental medicine for a rare blood cancer and complementing GSK’s Blenrep.

*GSK’s blood cancer medicine Blenrep failed to meet the primary goal of a late-stage research designed to demonstrate that it was superior to an existing treatment on the market*

The medicine obtained accelerated approval in the United States in 2020 and is currently approved as a therapy for patients with relapsed or refractory multiple myeloma who have had at least four prior therapies.

Blenrep was compared in the experiment to a combination of pomalidomide and low doses of the steroid dexamethasone. Celgene, which is now part of Bristol-Myers Squibb, developed pomalidomide, which was authorised as a therapy for multiple myeloma in 2013.

J.P.Morgan analysts noted in a note that findings from the so-called superiority trial termed DREAMM-3 may put into doubt Blenrep’s existing approval, adding that several regulatory scenarios now exist, including existing licences being revoked or authorities waiting for additional evidence.

“Overall, given these evidence putting into doubt Blenrep’s approvability in the current environment and the likelihood of success in previous treatment lines, we expect the market to price in the possibility that Blenrep authorisation is revoked,” they said.

GSK stated that results from the trial will be shared with health authorities, and that conversations are presently underway, with future Blenrep trials continuing as scheduled.

The medicine is part of a promising class of treatments known as antibody drug conjugates, which are designed antibodies that bind to cancer cells and then release cell-killing chemicals.

(In Bengaluru, Pushkala Aripaka and Amna Karimi contributed reporting, and Rashmi Aich, Uttaresh.V, and Susan Fenton edited the piece.)

To know more:

The FDA recommends parents against using infant head shaping pillows

The Food and Drug Administration advised parents on Thursday not to use infant head shaping pillows to affect a baby’s head shape or symmetry.

The FDA stated that head shaping pillows are unsafe for babies and can increase their “risk of suffocation and death.”

According to the government, these goods can create a “unsafe sleep environment” for babies and increase their “risk of suffocation and death,” as well as sudden infant death syndrome. According to the FDA, no such products have been approved.

Head shaping pillows are often shaped like a tiny mat that dips downward in the centre to cradle the back of an infant’s head. They are frequently formed like a distorted donut but can also be hearts or ovals with animal-like ears.

Some of these pillows are referred to as “infant head support pillows,” “head cushions,” “flat head pillows,” or “anti-flat head pillows.”
The FDA recommends parents against using infant head shaping pillows

Infants should sleep without any cushions, toys, loose bedding, or soft things nearby, according to the National Institutes of Health and the American Academy of Pediatrics. They should instead be placed on their backs in a naked crib on a flat surface.

According to the FDA, marketing claims for head shaping pillows frequently state that they can improve an infant’s head shape and symmetry, as well as prevent or treat flat head syndrome. However, the FDA stated that it is unaware of any “demonstrated benefit” of the goods for “any medical reason.”

Flat head syndrome, also known as positional plagiocephaly, occurs when a baby sleeps on the same side of the head for the first few months of life. According to Johns Hopkins All Children’s Hospital, this can result in a flat patch on one side or the rear of the head.

According to the FDA, flat head syndrome usually resolves on its own as the infant develops and does not cause any developmental problems.

Parents who are concerned about this, according to Johns Hopkins, should practise more supervised tummy time with their babies, change the direction their infant faces in the crib, or hold their baby more frequently.

“If you have an infant head shaping pillow, throw it away; do not donate or give it to anyone else,” the FDA said.

“The use of newborn head shape pillows may postpone the necessary examination and care of innocuous diseases, such as flat head syndrome, or more serious conditions, such as craniosynostosis,” the report continued. (Craniosynostosis is a condition in which the bones of a baby’s skull fuse together too soon.)

The FDA also encouraged doctors to discourage the use of infant head shaping pillows and to educate parents about the dangers they pose.

Catch Following Updates and Latest Studies:

Dermal fillers market rise up to USD 9.45 billion by 2030

Veterinary in Vitro Fertilization (IVF) Market Size Estimation, Share & Future Growth Trends Analysis, By Product Type (Reagents, Equipment, and Services), By Technique (Artificial Insemination, Embryo Transfer), By End Use (Fertility Clinics and Surgical Centers, Hospital, Research Laboratories, Cyrobanks), and Regional Analysis, 2022-2032

Orthopedic Implants Market Size Estimation, Share & Future Growth Trends Analysis, By Product (Joint Reconstruction Spinal Implants, Trauma Implants, Dental Implants, Orthobiologics, and Others), By End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others), and Regional Analysis, 2022-2030

Hospitalizations in New York City are on the rise as new COVID strains spread rapidly

Hospitalizations in New York City are on the rise because of the spread of novel COVID-19 subvariants that are more adept at circumventing immunity Flu and respiratory syncytial virus, or RSV, cases are also on the rise.

According to state data, approximately 1,100 COVID patients were hospitalized as of Oct. 24, up from 750 in mid-September, as reported by the New York Times. Case numbers have remained stable, albeit with many people testing at home and no data being collected, those figures are not accurate.

According to CDC data, the omicron sublineages known as BQ.1 and BQ.1.1 accounted for 42.5% of all cases in the New York region in the week ending Oct. 29, up from 37% the previous week.

This was higher than the BA.5 omicron subvariant, which accounted for 35.7% of new cases in the New York area in the previous week. The two sublineages were not even registered three weeks ago, illustrating how quickly they are spreading.

Experts are particularly concerned about a widespread outbreak of RSV, which can cause respiratory issues in young children and the elderly and for which no vaccination is presently available.

However, Pfizer Inc. reported on Tuesday that data from a late-stage trial of an RSV vaccine showed that it was beneficial in avoiding severe sickness in children as young as 6 months old.

The vaccine, administered to expectant moms, achieved a vaccination effectiveness of 81.8% in newborns from birth to the first 90 days of life in the Phase 3 trial. 69.4% effectiveness was established in the trial over the first 6 months of life.

Pfizer stated that it plans to file its first U.S. regulatory application for the vaccine by the end of 2022, followed by applications to additional regulatory bodies. It will also submit the trial results to a scientific journal for peer assessment.

Coronavirus Updates: Since the coronavirus epidemic began, MarketWatch’s daily roundup has been compiling and reporting on all the newest events every day.

Hospitalizations in New York City are on the rise because of the spread of novel COVID-19 subvariants that are more adept at circumventing immunity Flu and respiratory syncytial virus, or RSV, cases are also on the rise.

Other COVID-19 news to be aware of:

According to Reuters, Apple supplier Foxconn announced Tuesday that it has increased bonuses for workers at its Zhengzhou facility in central China in order to quell resentment over COVID limitations and retain staff at the massive iPhone assembly site. According to the official WeChat account of Foxconn’s Zhengzhou factory, daily bonuses for employees of a Foxconn unit responsible for creating electronics including smartphones have been increased to 400 yuan ($55) per day for November from 100 yuan. Workers deserted the site over the weekend to evade COVID limits after complaining on social media about their treatment and provisions.

To get more updates on Healthcare Industry: Dermal fillers market rise up to USD 9.45 billion by 2030

Dermal fillers market rise up to USD 9.45 billion by 2030

“Rising Interest in Cosmetic Operations Globally Fuels the Market”

Dermal filler market growth will be supported throughout the projected period by an expanding network of healthcare facilities offering cutting-edge aesthetic treatments and improved infrastructure. The number of clinics, medical spas, and centers for rejuvenation has significantly increased in recent years both in industrialized and developing countries. Thus, the rapid adoption of various non-invasive treatments offered by these facilities owing to the benefits including the cost-effectivity and shorter treatment duration will propel the industry growth. Furthermore, escalating number of skilled professionals such as dermatologists and plastic surgeons will further augment the industry expansion.

According to the recent study published by the Quintile Insights, The Dermal fillers market is expected to reach USD 9.45 billion by 2030; expanding at a CAGR of 7.44%. This is owing to recent product innovations, growing FDA approvals, cutting-edge aesthetic treatments, and improved healthcare infrastructure. High patient satisfaction from product development will also have a beneficial effect on product demand during the predicted period. In the coming years, it is anticipated that ongoing advancements in filler materials will have an impact on market expansion. Numerous products intended for particular facial regions have received FDA approval, enabling dermatologists to provide clients with specialized care. The filler can be used to treat moderate to severe facial creases and wrinkles.

***To learn more about this report,*** ***request a free sample copy***

Recent innovations, such as HA filler for subtle lip enhancement that improves lip definition without increasing lip size, will also raise public preference for dermal filler procedures. The surge in surgical and non-invasive cosmetic procedures worldwide is majorly responsible for the expansion of the market.

Dermal fillers are injected under the skin and are soft, gel-like materials. Deep under-eye bags, lifting of the cheekbones, volumization of the lips, smoothing of lip lines and nasolabial folds (the wrinkles that run from the side of the nose to the corners of the mouth), and hand rejuvenation are a few of the frequent issues they can treat.

Throughout the projected period, North America will continue to be one of the most attractive markets for dermal fillers. The region’s high disposable income, good ability to spend on cosmetic operations, the presence of top manufacturers and the expanding demand for non-surgical procedures in the region are some of the main drivers promoting expansion.

During the projected period, Europe is anticipated to hold the second-largest market share for dermal fillers. The region’s market is expected to be significantly influenced by the rising demand for minimally invasive methods of face enhancement.

Due to the rising geriatric population and rising per capita income, APAC is anticipated to expand at the fastest CAGR throughout the projection period. Another significant factor that is anticipated to propel the market in the area during the assessment period is the increased demand for non-invasive cosmetic procedures and products for facial aesthetics. Due to the presence of profitable chances that might accelerate the industry, the presence of growing nations like India, China, and Japan is anticipated to significantly enhance the regional market.

To increase their consumer base in the worldwide market, the majority of significant competitors are implementing a variety of competitive methods, including acquisition, mergers, and alliances. They are also emphasizing expanding their product lines. Numerous advances and product innovations are anticipated as a result of the rising demand for minimally invasive cosmetic procedures, giving them an advantage over their rivals.

Recent Developments:

In March 2021, with a modified administration regimen, Galderma announced the reintroduction of Sculptra (injectable Poly-L-lactic acid) in Europe.
In February 2021, the injectable hyaluronic acid filler BELOTERO BALANCE (+) with lidocaine has been launched in the United States, according to Merz Esthetics.

Ask for detailed information from the Author of the Research Study: https://quintileinsights.com/enquiry/request-sample/120299-global-dermal-fillers-market

Contact Us:

Samidha Jain
sales@quintileinsights.com